Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Ohio State University Comprehensive Cancer Center
Study ID
NCT02940301
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Classical Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ibrutinib — DRUG
    Given PO
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Nivolumab — BIOLOGICAL
    Given IV

Study Details

This phase II trial studies how well ibrutinib and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back or has not responded to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. Giving ibrutinib and nivolumab may work better in treating patients with classical Hodgkin lymphoma.

Key Dates

Start date
Dec 20, 2016
Status verified
Feb 2026
Primary completion
Aug 15, 2026
Completion
Aug 15, 2026

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ibrutinib, nivolumab)
    Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Proportion of patients in CR [ Time Frame: Up to course 7 (147 days) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Winship Cancer Center of Emory UniversityAtlantaGeorgia30322-
Ohio State University Comprehensive Cancer CenterColumbusOhio43210-

Find similar trials in Atlanta, GA

By research site
Winship Cancer Center of Emory University· Atlanta, GAOhio State University Comprehensive Cancer Center· Columbus, OH

Related Studies